NiKang Therapeutics Valuation, Funding & Investors

Synmosa Biopharma Corp is engaged in the research and development, manufacturing, marketing, and distribution of pharmaceutical products, medical devices, cosmetics, animal drugs, chemical food additives, and beverages. It is also involved in manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. The company provides prescription, OTC medicines, and healthcare products under its Synmosa trademark. The reporting segments of the company are; the Generic Drugs segment which derives key revenue, and the Active Pharmaceutical Ingredients segment.

Jixing Pharmaceuticals is a Shanghai-headquartered biotechnology firm developing therapeutics for cardiovascular and ophthalmic conditions. Its pipeline features JS201 for hypertrophic cardiomyopathy, JS102 for heart failure, JS301 for presbyopia and dry eye, and JS401 for hypertension, with multiple candidates in Phase 2 and 3 trials. Founded in 2019, the company has secured over $300 million in funding and collaborates with global pharma partners.

Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company’s business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital’s daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.

YungShin Global Holding Co Ltd invests, manufactures, and sells medicines, animal drugs, agricultural chemicals, industrial medicine, and cosmetics. The company derives revenue from the sale of Human drugs, Health food, Animal drugs, and Others. The company generates the majority of its revenue from Human drugs. Geographically, the company generates the revenue from Taiwan, the USA, Japan, and China, out of which the majority of its revenue is generated from Taiwan.

Yantai Lannacheng Biotechnology is a Yantai-based biotechnology company that develops class I integrated platforms for diagnosis and therapy using novel nuclear radiopharmaceuticals targeting tumors. The firm advances research in targeted radionuclide therapies and diagnostic agents for oncology applications. Its platform supports development of precision medicines for cancer treatment in China.

Qyuns Therapeutics Co Ltd is a a clinical-stage biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline. It has built a pipeline that covers the four disease areas in the field, including skin, rheumatic, respiratory and digestive diseases Key revenue is generated from PRC.

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.

Hyundai Bioscience Co Ltd is a Korean biotechnology company. The company is engaged in developing and commercializing bio-fusion technology with the purpose of delivering active ingredients safely and efficiently to the body. It has developed Vitabrid CG, a biomaterial that binds vitamin C with bio-friendly mineral layers, which is a beneficial ingredient in skin brightening, anti-aging, and anti-inflammation; and Vitabrid C12, a premium skincare brand.

Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.

Triastek is a Nanjing-based pharmaceutical company pioneering 3D-printed solid oral dosage forms. Its technology platform produces personalized tablets with controlled release profiles for complex drugs. The firm has submitted New Drug Applications to the FDA for printlets treating epilepsy and hypertension, with commercial manufacturing facilities in China.

TransThera Sciences (Nanjing) Inc is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing inventive small molecule therapies for oncology, inflammatory and cardiometabolic diseases. It has internally discovered and developed one Core Product Tinengotinib (TT-00420) and built a pipeline of five clinical stage product candidates and one preclinical stage product candidate with its fully-integrated in-house R&D system. Its Core Product Tinengotinib is a unique multi-targeted kinase (MTK) inhibitor targeting three key pathways. It is undergoing two pivotal/registrational clinical trials for the treatment of cholangiocarcinoma that has progressed following prior FGFR inhibitor therapy, one being conducted in China.

Rivus Pharmaceuticals is a San Diego-based biopharma company developing controlled metabolic accelerators for cardio-metabolic diseases. Its lead candidate targets obesity and heart failure by modulating fat metabolism. Clinical trials in phase 2 enroll patients across the US and Europe.

Casma Therapeutics is a biotechnology company engineering small molecules to modulate autophagy for treating neurodegenerative and muscle diseases. Cambridge, Massachusetts-headquartered, it targets lysosomal storage disorders and inflammation through selective TFEB and ULK1 activators. The firm advanced its lead candidate into preclinical studies for Parkinson's disease models.

SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.

LYNK Pharmaceuticals is a Hangzhou, Zhejiang-headquartered biotechnology firm founded in 2018, focused on discovering and developing novel small-molecule drugs targeting oncology, immunology, and inflammatory diseases.